Search

Your search keyword '"Piekarz, Richard L."' showing total 180 results
Start Over Author "Piekarz, Richard L."
180 results on '"Piekarz, Richard L."'

1. Intravenous 5-fluoro-2′-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors

Author

Coyne, Geraldine O.’Sullivan, Wang, Lihua, Zlott, Jennifer, Juwara, Lamin, Covey, Joseph M., Beumer, Jan H., Cristea, Mihaela C., Newman, Edward M., Koehler, Stephen, Nieva, Jorge J., Garcia, Agustin A., Gandara, David R., Miller, Brandon, Khin, Sonny, Miller, Sarah B., Steinberg, Seth M., Rubinstein, Larry, Parchment, Ralph E., Kinders, Robert J., Piekarz, Richard L., Kummar, Shivaani, Chen, Alice P., and Doroshow, James H.

Published
2020
Full Text
View/download PDF

3. Data from Inhibition of Parp1 by BMN673 Effectively Sensitizes Cells to Radiotherapy by Upsetting the Balance of Repair Pathways Processing DNA Double-Strand Breaks

Author

Soni, Aashish, primary, Li, Fanghua, primary, Wang, You, primary, Grabos, Martha, primary, Krieger, Lisa Marie, primary, Chaudhary, Shipra, primary, Hasan, Mohammad Sharif Mortoga, primary, Ahmed, Mansoor, primary, Coleman, C. Norman, primary, Teicher, Beverly A., primary, Piekarz, Richard L., primary, Wang, Dian, primary, and Iliakis, George E., primary

Published
2023
Full Text
View/download PDF

4. Figure S4 from Inhibition of Parp1 by BMN673 Effectively Sensitizes Cells to Radiotherapy by Upsetting the Balance of Repair Pathways Processing DNA Double-Strand Breaks

Author

Soni, Aashish, primary, Li, Fanghua, primary, Wang, You, primary, Grabos, Martha, primary, Krieger, Lisa Marie, primary, Chaudhary, Shipra, primary, Hasan, Mohammad Sharif Mortoga, primary, Ahmed, Mansoor, primary, Coleman, C. Norman, primary, Teicher, Beverly A., primary, Piekarz, Richard L., primary, Wang, Dian, primary, and Iliakis, George E., primary

Published
2023
Full Text
View/download PDF

5. Tables S1, S2, S3 from Inhibition of Parp1 by BMN673 Effectively Sensitizes Cells to Radiotherapy by Upsetting the Balance of Repair Pathways Processing DNA Double-Strand Breaks

Author

Soni, Aashish, primary, Li, Fanghua, primary, Wang, You, primary, Grabos, Martha, primary, Krieger, Lisa Marie, primary, Chaudhary, Shipra, primary, Hasan, Mohammad Sharif Mortoga, primary, Ahmed, Mansoor, primary, Coleman, C. Norman, primary, Teicher, Beverly A., primary, Piekarz, Richard L., primary, Wang, Dian, primary, and Iliakis, George E., primary

Published
2023
Full Text
View/download PDF

6. Safety-Modified Episomal Vectors for Human Gene Therapy

Author

Cooper, Mark J., Lippa, Mara, Payne, Jennifer M., Hatzivassiliou, Georgia, Reifenberg, Erica, Fayazi, Behnaz, Perales, Jose C., Morrison, Laura J., Templeton, Dennis, Piekarz, Richard L., and Tan, June

Published
1997

8. Supplementary Figure 4 from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for KATP Channel

Author

Noonan, Anne M., primary, Eisch, Robin A., primary, Liewehr, David J., primary, Sissung, Tristan M., primary, Venzon, David J., primary, Flagg, Thomas P., primary, Haigney, Mark C., primary, Steinberg, Seth M., primary, Figg, William D., primary, Piekarz, Richard L., primary, and Bates, Susan E., primary

Published
2023
Full Text
View/download PDF

9. Supplementary Figure 5 from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for KATP Channel

Author

Noonan, Anne M., primary, Eisch, Robin A., primary, Liewehr, David J., primary, Sissung, Tristan M., primary, Venzon, David J., primary, Flagg, Thomas P., primary, Haigney, Mark C., primary, Steinberg, Seth M., primary, Figg, William D., primary, Piekarz, Richard L., primary, and Bates, Susan E., primary

Published
2023
Full Text
View/download PDF

10. Supplementary Figure 3 from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for KATP Channel

Author

Noonan, Anne M., primary, Eisch, Robin A., primary, Liewehr, David J., primary, Sissung, Tristan M., primary, Venzon, David J., primary, Flagg, Thomas P., primary, Haigney, Mark C., primary, Steinberg, Seth M., primary, Figg, William D., primary, Piekarz, Richard L., primary, and Bates, Susan E., primary

Published
2023
Full Text
View/download PDF

11. Supplementary Figure S1 from Impact of ABCB1 Allelic Variants on QTc Interval Prolongation

Author

Sissung, Tristan M., primary, Gardner, Erin R., primary, Piekarz, Richard L., primary, Howden, Reuben, primary, Chen, Xiaohong, primary, Woo, Sukyung, primary, Franke, Ryan, primary, Clark, James A., primary, Miller-DeGraff, Laura, primary, Steinberg, Seth M., primary, Venzon, David, primary, Liewehr, David, primary, Kleeberger, Steven R., primary, Bates, Susan E., primary, Price, Douglas K., primary, Rosing, Douglas R., primary, Cabell, Christopher, primary, Sparreboom, Alex, primary, and Figg, William D., primary

Published
2023
Full Text
View/download PDF

12. Supplementary Tables from Phase I Trial of a New Schedule of Romidepsin in Patients with Advanced Cancers

Author

Amiri-Kordestani, Laleh, primary, Luchenko, Victoria, primary, Peer, Cody J., primary, Ghafourian, Kambiz, primary, Reynolds, James, primary, Draper, Deb, primary, Frye, Robin, primary, Woo, Sue, primary, Venzon, David, primary, Wright, John, primary, Skarulis, Monica, primary, Figg, William D., primary, Fojo, Tito, primary, Bates, Susan E., primary, and Piekarz, Richard L., primary

Published
2023
Full Text
View/download PDF

13. Supplementary Data from A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer

Author

Kelly, Ronan J., primary, Draper, Deborah, primary, Chen, Clara C., primary, Robey, Robert W., primary, Figg, William D., primary, Piekarz, Richard L., primary, Chen, Xiaohong, primary, Gardner, Erin R., primary, Balis, Frank M., primary, Venkatesan, Aradhana M., primary, Steinberg, Seth M., primary, Fojo, Tito, primary, and Bates, Susan E., primary

Published
2023
Full Text
View/download PDF

14. Data from Phase I Trial of a New Schedule of Romidepsin in Patients with Advanced Cancers

Author

Amiri-Kordestani, Laleh, primary, Luchenko, Victoria, primary, Peer, Cody J., primary, Ghafourian, Kambiz, primary, Reynolds, James, primary, Draper, Deb, primary, Frye, Robin, primary, Woo, Sue, primary, Venzon, David, primary, Wright, John, primary, Skarulis, Monica, primary, Figg, William D., primary, Fojo, Tito, primary, Bates, Susan E., primary, and Piekarz, Richard L., primary

Published
2023
Full Text
View/download PDF

15. Supplementary Figure 1 from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for KATP Channel

Author

Noonan, Anne M., primary, Eisch, Robin A., primary, Liewehr, David J., primary, Sissung, Tristan M., primary, Venzon, David J., primary, Flagg, Thomas P., primary, Haigney, Mark C., primary, Steinberg, Seth M., primary, Figg, William D., primary, Piekarz, Richard L., primary, and Bates, Susan E., primary

Published
2023
Full Text
View/download PDF

16. Supplementary Figure 8 from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for KATP Channel

Author

Noonan, Anne M., primary, Eisch, Robin A., primary, Liewehr, David J., primary, Sissung, Tristan M., primary, Venzon, David J., primary, Flagg, Thomas P., primary, Haigney, Mark C., primary, Steinberg, Seth M., primary, Figg, William D., primary, Piekarz, Richard L., primary, and Bates, Susan E., primary

Published
2023
Full Text
View/download PDF

17. Supplementary Figure 2 from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for KATP Channel

Author

Noonan, Anne M., primary, Eisch, Robin A., primary, Liewehr, David J., primary, Sissung, Tristan M., primary, Venzon, David J., primary, Flagg, Thomas P., primary, Haigney, Mark C., primary, Steinberg, Seth M., primary, Figg, William D., primary, Piekarz, Richard L., primary, and Bates, Susan E., primary

Published
2023
Full Text
View/download PDF

18. Supplementary Figure 1 from Phase I Trial of a New Schedule of Romidepsin in Patients with Advanced Cancers

Author

Amiri-Kordestani, Laleh, primary, Luchenko, Victoria, primary, Peer, Cody J., primary, Ghafourian, Kambiz, primary, Reynolds, James, primary, Draper, Deb, primary, Frye, Robin, primary, Woo, Sue, primary, Venzon, David, primary, Wright, John, primary, Skarulis, Monica, primary, Figg, William D., primary, Fojo, Tito, primary, Bates, Susan E., primary, and Piekarz, Richard L., primary

Published
2023
Full Text
View/download PDF

19. Data from Impact of ABCB1 Allelic Variants on QTc Interval Prolongation

Author

Sissung, Tristan M., primary, Gardner, Erin R., primary, Piekarz, Richard L., primary, Howden, Reuben, primary, Chen, Xiaohong, primary, Woo, Sukyung, primary, Franke, Ryan, primary, Clark, James A., primary, Miller-DeGraff, Laura, primary, Steinberg, Seth M., primary, Venzon, David, primary, Liewehr, David, primary, Kleeberger, Steven R., primary, Bates, Susan E., primary, Price, Douglas K., primary, Rosing, Douglas R., primary, Cabell, Christopher, primary, Sparreboom, Alex, primary, and Figg, William D., primary

Published
2023
Full Text
View/download PDF

20. Supplementary Methods from Impact of ABCB1 Allelic Variants on QTc Interval Prolongation

Author

Sissung, Tristan M., primary, Gardner, Erin R., primary, Piekarz, Richard L., primary, Howden, Reuben, primary, Chen, Xiaohong, primary, Woo, Sukyung, primary, Franke, Ryan, primary, Clark, James A., primary, Miller-DeGraff, Laura, primary, Steinberg, Seth M., primary, Venzon, David, primary, Liewehr, David, primary, Kleeberger, Steven R., primary, Bates, Susan E., primary, Price, Douglas K., primary, Rosing, Douglas R., primary, Cabell, Christopher, primary, Sparreboom, Alex, primary, and Figg, William D., primary

Published
2023
Full Text
View/download PDF

21. Supplementary Results from Impact of ABCB1 Allelic Variants on QTc Interval Prolongation

Author

Sissung, Tristan M., primary, Gardner, Erin R., primary, Piekarz, Richard L., primary, Howden, Reuben, primary, Chen, Xiaohong, primary, Woo, Sukyung, primary, Franke, Ryan, primary, Clark, James A., primary, Miller-DeGraff, Laura, primary, Steinberg, Seth M., primary, Venzon, David, primary, Liewehr, David, primary, Kleeberger, Steven R., primary, Bates, Susan E., primary, Price, Douglas K., primary, Rosing, Douglas R., primary, Cabell, Christopher, primary, Sparreboom, Alex, primary, and Figg, William D., primary

Published
2023
Full Text
View/download PDF

22. Supplementary Figure Legends from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for KATP Channel

Author

Noonan, Anne M., primary, Eisch, Robin A., primary, Liewehr, David J., primary, Sissung, Tristan M., primary, Venzon, David J., primary, Flagg, Thomas P., primary, Haigney, Mark C., primary, Steinberg, Seth M., primary, Figg, William D., primary, Piekarz, Richard L., primary, and Bates, Susan E., primary

Published
2023
Full Text
View/download PDF

23. Supplementary Figure 6 from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for KATP Channel

Author

Noonan, Anne M., primary, Eisch, Robin A., primary, Liewehr, David J., primary, Sissung, Tristan M., primary, Venzon, David J., primary, Flagg, Thomas P., primary, Haigney, Mark C., primary, Steinberg, Seth M., primary, Figg, William D., primary, Piekarz, Richard L., primary, and Bates, Susan E., primary

Published
2023
Full Text
View/download PDF

24. Supplementary Figure 7 from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for KATP Channel

Author

Noonan, Anne M., primary, Eisch, Robin A., primary, Liewehr, David J., primary, Sissung, Tristan M., primary, Venzon, David J., primary, Flagg, Thomas P., primary, Haigney, Mark C., primary, Steinberg, Seth M., primary, Figg, William D., primary, Piekarz, Richard L., primary, and Bates, Susan E., primary

Published
2023
Full Text
View/download PDF

26. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

Author

Piekarz, Richard L., Frye, Robin, Prince, H. Miles, Kirschbaum, Mark H., Zain, Jasmine, Allen, Steven L., Jaffe, Elaine S., Ling, Alexander, Turner, Maria, Peer, Cody J., Figg, William D., Steinberg, Seth M., Smith, Sonali, Joske, David, Lewis, Ian, Hutchins, Laura, Craig, Michael, Fojo, A. Tito, Wright, John J., and Bates, Susan E.

Published
2011
Full Text
View/download PDF

27. E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor–Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group

Author

Connolly, Roisin M., primary, Zhao, Fengmin, additional, Miller, Kathy D., additional, Lee, Min-Jung, additional, Piekarz, Richard L., additional, Smith, Karen L., additional, Brown-Glaberman, Ursa A., additional, Winn, Jennifer S., additional, Faller, Bryan A., additional, Onitilo, Adedayo A., additional, Burkard, Mark E., additional, Budd, George T., additional, Levine, Ellis G., additional, Royce, Melanie E., additional, Kaufman, Peter A., additional, Thomas, Alexandra, additional, Trepel, Jane B., additional, Wolff, Antonio C., additional, and Sparano, Joseph A., additional

Published
2021
Full Text
View/download PDF

28. Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data

Author

Bates, Susan E., Eisch, Robin, Ling, Alexander, Rosing, Douglas, Turner, Maria, Pittaluga, Stefania, Prince, Miles H., Kirschbaum, Mark H., Allen, Steven L., Zain, Jasmine, Geskin, Larisa J., Joske, David, Popplewell, Leslie, Cowen, Edward W., Jaffe, Elaine S., Nichols, Jean, Kennedy, Sally, Steinberg, Seth M., Liewehr, David J., Showe, Louise C., Steakley, Caryn, Wright, John, Fojo, Tito, Litman, Thomas, and Piekarz, Richard L.

Published
2015
Full Text
View/download PDF

29. Abstract GS4-02: E2112: Randomized phase 3 trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. A trial of the ECOG-ACRIN cancer research group

Author

Connolly, Roisin M, primary, Zhao, Fengmin, additional, Miller, Kathy D, additional, Lee, Min-Jung, additional, Piekarz, Richard L, additional, Smith, Karen L, additional, Brown-Glaberman, Ursa, additional, Winn, Jennifer S, additional, Faller, Bryan A, additional, Onitilo, Adedayo A, additional, Burkard, Mark E, additional, Budd, George T, additional, Levine, Ellis G, additional, Royce, Melanie E, additional, Kaufman, Peter A, additional, Thomas, Alexandra, additional, Trepel, Jane B, additional, Wolff, Antonio C, additional, and Sparano, Joseph A, additional

Published
2021
Full Text
View/download PDF

37. Evaluation of different recall periods for the US National Cancer Institute���s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

Author

Mendoza, Tito R., Dueck, Amylou C., Bennett, Antonia V., Mitchell, Sandra A., Reeve, Bryce B., Atkinson, Thomas M., Li, Yuelin, Castro, Kathleen M., Denicoff, Andrea, Rogak, Lauren J., Piekarz, Richard L., Cleeland, Charles S., Sloan, Jeff, Schrag, Deborah, and Basch, Ethan

Subjects
Adult, Male, Time Factors, Drug-Related Side Effects and Adverse Reactions, Antineoplastic Agents, Chemoradiotherapy, Middle Aged, Article, National Cancer Institute (U.S.), United States, Young Adult, Neoplasms, Mental Recall, Adverse Drug Reaction Reporting Systems, Humans, Female, Patient Reported Outcome Measures, Self Report, Aged
Abstract

Aims���The U.S. National Cancer Institute recently developed the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). PRO-CTCAE is a library of questions for clinical trial participants to self-report symptomatic adverse events (e.g., nausea). The objective of this study is to inform evidence-based selection of a recall period when PRO-CTCAE is included in a trial. We evaluated differences between 1-week, 2-week, 3-week, and 4-week recall periods, using daily reporting as the reference. Methods���English-speaking patients with cancer receiving chemotherapy and/or radiotherapy were enrolled at four U.S. cancer centers and affiliated community clinics. Participants completed 27 PRO-CTCAE items electronically daily for 28 days, and then weekly over 4 weeks, using 1-week, 2-week, 3-week, and 4-week recall periods. For each recall period, mean differences, effect sizes, and intraclass correlation coefficients were calculated to evaluate agreement between the maximum of daily ratings and the corresponding ratings obtained using longer recall periods (e.g., maximum of daily scores over 7 days vs. 1-week recall). Analyses were repeated using the average of daily scores within each recall period rather than the maximum of daily scores. Results���127 subjects completed questionnaires (57% male; median age 57). The median of the 27 mean differences in scores on the PRO-CTCAE 5-point response scale comparing the maximum daily versus the longer recall period (and corresponding effect size), was ���0.20 (���0.20) for 1-week recall; ���0.36 (���0.31) for 2-week recall; ���0.45 (���0.39) for 3-week recall; and ���0.47 (���0.40) for 4-week recall. The median intraclass correlation across 27 items between the maximum of daily ratings and the corresponding longer recall ratings for 1-week recall was 0.70 (range: 0.54���0.82); 2-week recall: 0.74 (range: 0.58���0.83); 3-week recall: 0.72 (range: 0.61���0.84); and 4-week recall: 0.72 (range: 0.64���0.86). Similar results were observed for all analyses using the average of daily scores rather than the maximum of daily scores. Conclusions���1-week recall corresponds best to daily reporting. Although intraclass correlations remain stable over time, there are small but progressively larger differences between daily and longer recall periods at 2, 3, and 4 weeks, respectively. The preferred recall period for the PRO-CTCAE is the past 7 days, although investigators may opt for recall periods of 2, 3, or 4 weeks with an understanding that there may be some information loss.

Published
2017
Full Text
View/download PDF

38. Inhibition of Parp1 by BMN673 Effectively Sensitizes Cells to Radiotherapy by Upsetting the Balance of Repair Pathways Processing DNA Double-Strand Breaks

Author

Soni, Aashish, primary, Li, Fanghua, additional, Wang, You, additional, Grabos, Martha, additional, Krieger, Lisa Marie, additional, Chaudhary, Shipra, additional, Hasan, Mohammad Sharif Mortoga, additional, Ahmed, Mansoor, additional, Coleman, C. Norman, additional, Teicher, Beverly A., additional, Piekarz, Richard L., additional, Wang, Dian, additional, and Iliakis, George E., additional

Published
2018
Full Text
View/download PDF

39. Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung

Author

Balasubramaniam, Sanjeeve, primary, Redon, Christophe E., additional, Peer, Cody J., additional, Bryla, Christine, additional, Lee, Min-Jung, additional, Trepel, Jane B., additional, Tomita, Yusuke, additional, Rajan, Arun, additional, Giaccone, Giuseppe, additional, Bonner, William M., additional, Figg, William D., additional, Fojo, Tito, additional, Piekarz, Richard L., additional, and Bates, Susan E., additional

Published
2018
Full Text
View/download PDF

40. Use of PRO Measures to Inform Tolerability in Oncology Trials: Implications for Clinical Review, IND Safety Reporting, and Clinical Site Inspections

Author

Kim, Janice, primary, Singh, Harpreet, additional, Ayalew, Kassa, additional, Borror, Kristina, additional, Campbell, Michelle, additional, Johnson, Laura Lee, additional, Karesh, Alyson, additional, Khin, Ni A., additional, Less, Joanne R., additional, Menikoff, Jerry, additional, Minasian, Lori, additional, Mitchell, Sandra A., additional, Papadopoulos, Elektra J., additional, Piekarz, Richard L., additional, Prohaska, Kevin A., additional, Thompson, Susan, additional, Sridhara, Rajeshwari, additional, Pazdur, Richard, additional, and Kluetz, Paul G., additional

Published
2018
Full Text
View/download PDF

41. A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma

Author

Goncalves, Priscila H., primary, Heilbrun, Lance K., additional, Barrett, Michael T., additional, Kummar, Shivaani, additional, Hansen, Aaron R., additional, Siu, Lillian L., additional, Piekarz, Richard L., additional, Sukari, Ammar W., additional, Chao, Joseph, additional, Pilat, Mary Jo, additional, Smith, Daryn W., additional, Casetta, Lindsay, additional, Boerner, Scott A., additional, Chen, Alice, additional, Lenkiewicz, Elizabeth, additional, Malasi, Smriti, additional, and LoRusso, Patricia M., additional

Published
2017
Full Text
View/download PDF

42. Evaluation of different recall periods for the US National Cancer Institute’s PRO-CTCAE

Author

Mendoza, Tito R, primary, Dueck, Amylou C, additional, Bennett, Antonia V, additional, Mitchell, Sandra A, additional, Reeve, Bryce B, additional, Atkinson, Thomas M, additional, Li, Yuelin, additional, Castro, Kathleen M, additional, Denicoff, Andrea, additional, Rogak, Lauren J, additional, Piekarz, Richard L, additional, Cleeland, Charles S, additional, Sloan, Jeff A., additional, Schrag, Deborah, additional, and Basch, Ethan, additional

Published
2017
Full Text
View/download PDF

44. Abstract OT2-1-06: E2112: A randomized phase III trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer

Author

Connolly, Roisin M, primary, Zhao, Fengmin, additional, Miller, Kathy D, additional, Tevaarwerk, Amye J, additional, Wagner, Lynne I, additional, Lee, Min-Jung, additional, Murray, Judy, additional, Gray, Robert, additional, Piekarz, Richard L, additional, Zujewski, Jo Anne A, additional, and Sparano, Joseph A, additional

Published
2015
Full Text
View/download PDF

45. Abstract 5536: Short-term romidepsin treatment combined with MAPK pathway inhibition results in decreased mitochondrial hexokinase 2, increased mitochondrial Bim and apoptosis in BRAF mutant cancers

Author

Bates, Susan E., primary, Luchenko, Victoria, additional, Basseville, Agnes, additional, Bahr, Julian, additional, Chakraborty, Arup R., additional, McDonald, Andrew, additional, Zimmer, Alexandra, additional, Piekarz, Richard L., additional, and Robey, Robert W., additional

Published
2014
Full Text
View/download PDF

46. Phase I Trial of a New Schedule of Romidepsin in Patients with Advanced Cancers

Author

Amiri-Kordestani, Laleh, primary, Luchenko, Victoria, additional, Peer, Cody J., additional, Ghafourian, Kambiz, additional, Reynolds, James, additional, Draper, Deb, additional, Frye, Robin, additional, Woo, Sue, additional, Venzon, David, additional, Wright, John, additional, Skarulis, Monica, additional, Figg, William D., additional, Fojo, Tito, additional, Bates, Susan E., additional, and Piekarz, Richard L., additional

Published
2013
Full Text
View/download PDF

47. Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for KATP Channel

Author

Noonan, Anne M., primary, Eisch, Robin A., additional, Liewehr, David J., additional, Sissung, Tristan M., additional, Venzon, David J., additional, Flagg, Thomas P., additional, Haigney, Mark C., additional, Steinberg, Seth M., additional, Figg, William D., additional, Piekarz, Richard L., additional, and Bates, Susan E., additional

Published
2013
Full Text
View/download PDF

50. Impact of ABCB1 Allelic Variants on QTc Interval Prolongation

Author

Sissung, Tristan M., primary, Gardner, Erin R., additional, Piekarz, Richard L., additional, Howden, Reuben, additional, Chen, Xiaohong, additional, Woo, Sukyung, additional, Franke, Ryan, additional, Clark, James A., additional, Miller-DeGraff, Laura, additional, Steinberg, Seth M., additional, Venzon, David, additional, Liewehr, David, additional, Kleeberger, Steven R., additional, Bates, Susan E., additional, Price, Douglas K., additional, Rosing, Douglas R., additional, Cabell, Christopher, additional, Sparreboom, Alex, additional, and Figg, William D., additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results